Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease

Gut

Volumn 62, Issue 3, 2013, Pages 387-394

  Waterman, Matti ^a,b   Xu, Wei ^c   Dinani, Amreen ^a,b   Steinhart, A Hillary ^a,b,c   Croitoru, Kenneth ^a,b,c   Nguyen, Geoffrey C ^a,b,c   McLeod, Robin S ^a,b,c   Greenberg, Gordon R ^a,b,c   Cohen, Zane ^a,b,c   Silverberg, Mark S ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Zane Cohen Centre for Digestive Diseases   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; BIOLOGICAL PRODUCT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL SURGERY; ADULT; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG EXPOSURE; ENTERITIS; FEMALE; FEVER; HOSPITAL READMISSION; HUMAN; INFECTION RATE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; SURGICAL INFECTION; TREATMENT DURATION; ULCERATIVE COLITIS; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LENGTH OF STAY; MALE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; URINARY TRACT INFECTIONS; WOUND INFECTION; YOUNG ADULT;

EID: 84873380932     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301495     Document Type: Article

References (19)

1. Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:103-9.
2. Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol 2010;105:2009-16.
3. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterol 2009;137:502-11.
4. De Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101.
5. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53.
6. Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83. (Pubitemid 39090217)
7. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730-6.
8. Appau KA, Fazzio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008;12:1738-44.
9. Mor IJ, Vogel JD, Da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51:1202-7.
10. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-54. (Pubitemid 38496640)
11. Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010;31:486-92.
12. Holubar SD, Cima RR, Pemberton JH. Does infliximab increase complications after surgery for inflammatory bowel disease? F1000 Med Rep 2009;1:pii:10.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Supp A: 5-36.
14. Baert F, Noman M, Vermiere S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
15. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Col Surg 2007;204:956-62; discussion 962-3. (Pubitemid 46661200)
16. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007;50:1747-53. (Pubitemid 350077092)
17. Holubar SD, Dozoiz EJ, Privitera A, et al. Minimally invasive colectomy for Crohn's colitis: a single institution experience. Inflamm Bowel Dis 2010;16:1940-6.
18. Ferrante M, D'Hoore A, Vermiere S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062-70.
19. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients Gastroenterolog 2003;125:320-7.